NEW YORK (TheStreet) -- InterMune (ITMN) shares continue to climb on heavy volume Tuesday, up 0.2% to $73, after the company agreed to be bought by Swiss pharmaceutical company Roche for $8.3 billion.
See what Jim Cramer thinks of Roche's bid for InterMune:
More than 12.5 million shares have been traded so far today, more than six times its three-month daily average.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.